Of major importance to diabetic patients is the effect of SGLT-2 inhibitors on the course of cardiovascular complications to which they are particularly predisposed, such as acute coronary syndromes, especially acute myocardial infarction (AMI). The gene discussed is SLC5A2; the disease is myocardial infarction.